Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
129.1 USD | -0.72% | +1.45% | +18.71% |
03:02pm | Merck: phase 3 trial in melanoma halted | CF |
02:05pm | Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study | DJ |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.71% | 329B | |
+29.80% | 684B | |
+29.45% | 568B | |
-4.04% | 361B | |
+4.56% | 284B | |
+15.89% | 240B | |
+9.33% | 208B | |
-7.03% | 200B | |
+7.66% | 166B | |
-1.53% | 159B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Transcript : Merck & Co., Inc. - Special Call